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TWEAKNon-proliferative proteinuric diseases are the most common primary glomerular disorders causing end-stage renal
disease. These disordersmay associate low level glomerular inﬂammation andpodocyte expression of inﬂammatory
mediators. However, the factors regulating podocyte expression of inﬂammatorymediators in vivo in non-immune
disorders are poorly understood. We have now explored the regulation and role of TWEAK receptor Fn14 in medi-
ating glomerular inﬂammation in cultured podocytes and in experimental and human non-immune proteinuria.
Transcriptomics disclosed Fn14 and MCP-1 mRNA upregulation in glomeruli from patients with focal segmental
glomerulosclerosis, as well as a correlation between the expression of both transcripts. Increased glomerular
Fn14 and MCP-1 mRNA was conﬁrmed in a second focal segmental glomerulosclerosis cohort and was also ob-
served in membranous nephropathy. In human non-proliferative proteinuric kidney diseases podocytes
displayed Fn14 and MCP-1 expression and NFκB activation. Podocyte Fn14 was increased in murine protein
overload-induced proteinuria. In Fn14 knock-out mice with protein overload-induced proteinuria, glomerular and
periglomerular macrophage inﬁltrates were reduced, as were MCP-1 mRNA and podocyte MCP-1 staining and
podocyte numbers preserved as compared to wild-type counterparts. Adenovirus-mediated overexpression of
TWEAK increasedperiglomerularmacrophage inﬁltration inmicewithout prior kidney injury. In culturedpodocytes
inﬂammatory cytokines increased Fn14 mRNA and protein levels. TWEAK activated NFκB and increased MCP-1
mRNA and protein, an effect prevented by the NFκB inhibitor parthenolide. In conclusion, Fn14 activation results
in NFκB-mediated pro-inﬂammatory effects on podocytes that may be relevant for the pathogenesis of non-
proliferative proteinuric kidney disease of non-immune origin.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Primary glomerulonephritides may be classiﬁed as proliferative or
non-proliferative. Proliferative glomerular injury is usually a response
to immune-mediated injury associated with prominent glomerular and
periglomerular inﬁltration by macrophages (10- to 10-fold increase in
the case of lupus nephritis and crescentic glomerulonephritis) [2,31].
Overt glomerular inﬂammation results in the clinical syndromes of rapid-
ly progressive glomerulonephritis or nephritic syndrome, encompassing
the coexistence of hematuria, proteinuria and rapid loss of renal function
that may lead to the need for renal replacement therapy in weeks–
few months. Despite the potentially dramatic clinical presentation ofd.
ción Jiménez Díaz, Avda Reyes
194; fax: +34 915 442636.
ights reserved.proliferative glomerular injury, non-proliferative nephropathies of non-
immune origin are a much more common cause of end-stage renal
disease (ESRD). Non-proliferative glomerulonephritides lack overt glo-
merular inﬂammation and clinically present proteinuria or nephrotic
syndrome that may evolve to ESRD over the course of years. Low-level
glomerular and periglomerular inﬂammation is present as evidenced by
a 2 to 7-fold increase in glomerular macrophages [2,24,31] in non-
proliferative diseases that may lead to ESRD such as focal segmental
glomerulosclerosis (FSGS) and membranous nephropathy (MN) [11].
However, no macrophage inﬁltration is observed in minimal change
disease (MCD), which does not progress to ESRD. Low-level inﬂamma-
tion is a key process in chronic diseases such as atherosclerosis and
diabetic nephropathy [15]. However, the factors regulating low-level glo-
merular inﬂammation in non-proliferative nephropathies are poorly un-
derstood. Non-immune podocyte injury leading to podocyte depletion
and subsequent tuft sclerosis is thought to underlie the pathogenesis of
FSGS [9,10]. By contrast, in MN podocytes are injured by antibodies
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tract inﬂammatory cells. Monocyte chemoattractant protein-1 (MCP-1),
also known as C–C chemokine ligand 2 (CCL2), is a potent mononuclear
cell chemoattractant expressed predominantly by glomerular podocytes
in non-proliferative proteinuric conditions, such as diabetic, hyperten-
sive, and membranous nephropathies [7,20,36,45]. MCP-1 activates the
C–C chemokine receptor 2 (CCR2) and is a major promoter of inﬂamma-
tion, renal injury, and ﬁbrosis in non-immune glomerulopathies, such
as the most prevalent one, diabetic nephropathy [17,62]. Therapeutic
targeting of MCP-1 has proven beneﬁcial in experimental glomerular
injury of non-immune origin, including protein overload proteinuria
and diabetic nephropathy [13,57,58]. Indeed, a dual CCR2/CCR5 chemo-
kine antagonist is undergoing clinical trials in human diabetic nephrop-
athy (http://clinicaltrials.gov/ct2/show/NCT01752985, accessed June 1,
2013). However, the drivers of podocyte expression of MCP-1 and
other inﬂammatory mediators, such as TNF and interleukins, in non-
proliferative glomerulonephritis are poorly characterized [42]. Under-
standing the regulation of MCP-1 expression in podocytes may identify
novel therapeutic approaches targeting upstream molecules. Non-
immune factors, such as advanced glycation end products (AGEs) [18]
and cytokines such as TNFα [60] increase MCP-1 expression in cultured
podocytes, but few functional studies have addressed their in vivo
relevance. Other members of the TNF superfamily of cytokines also reg-
ulate inﬂammation [1,28,34,35]. Tumor necrosis factor-likeweak induc-
er of apoptosis (TWEAK, TNFSF12) is amore recently describedmember
of the TNF superfamily [3,6,43,65] that induces the secretion of inﬂam-
matory mediators in mesangial and tubular epithelial cells through ac-
tivation of the Fibroblast growth factor-inducible 14 (Fn14) receptor
[5,51]. The role of TWEAK in experimental proliferative lupus nephritis
and tubular acute kidney injury has been established [38,51,66,67].
However, there is scarce information on the role of Fn14 in non-
immune podocyte injury. Neutralizing anti-TWEAKantibodies is under-
going clinical trials in immune-mediated, proliferative lupus nephritis
[47], a disease whose clinical manifestations are nephritic syndrome
or rapidly progressive glomerulonephritis. Preclinical studies are need-
ed that explore the therapeutic relevance of this pathway for diseases
presenting with proteinuria or nephrotic syndrome, that is, non-
proliferative proteinuric kidney diseases, and more speciﬁcally, those
of non-immune origin.
We have now explored for the ﬁrst time the contribution of
podocytes Fn14 to low level glomerular and periglomerular inﬂamma-
tion in non-immune human and experimental non-proliferative, pro-
teinuric kidney diseases. We now report that Fn14 activation results
in NFκB-dependent secretion of MCP1 by podocytes. We further show
that podocytes express Fn14 and MCP1 in vivo in human and experi-
mental non-immune, non-proliferative proteinuric kidney disease and
that the absence of Fn14 decreases glomerular macrophage inﬁltration
and podocyte MCP1 in experimental proteinuria.2. Material and methods
2.1. Cells and reagents
Conditionally immortalized mouse podocytes were a kind gift by
Peter Mundel and were cultured as described [39]. Podocytes were
propagated on type I collagen (Biochrom, Berlin, Germany) at 33 °C
in the presence of 10 U/ml mouse recombinant interferon (IFN-γ)
(Immugenex, Los Angeles, CA) (permissive conditions) to enhance
expression of a thermosensitive T antigen. Once cells had reached 70
to 80% conﬂuence, differentiation and a quiescent phenotype were
induced by culturing under “non-permissive conditions” at 37 °C
without INF-γ for N12 days, resulting in disappearance of T antigen. Cul-
ture medium was RPMI 1640 (GIBCO, Grand Island, NY), medium that
contained 10% heat-inactivated fetal bovine serum (FBS), 2 mM gluta-
mine, 100 U/ml penicillin and 100 μg/ml streptomycin. For experimentscells were cultured in serum-free media 24 h previous to the addition
of the stimuli and throughout the experiment.
Recombinant TWEAK (Alexis, Läufelﬁngen, Switzerland) was
dissolved in water and used at 100 ng/ml. Murine TNFα (PrePotech,
London, UK) 30 ng/ml and interferon-γ (PrePotech) 30 U/ml were
used in some experiments. Parthenolide (Sigma, St. Louis, MO) was
used at 10 μM, a concentration shown to inhibit NFκB inmurine tubular
epithelial MCT cells without decreasing cell viability [51].
2.2. Western blot
Western blots were performed as described previously [49].
Membranes were incubated overnight at 4 °C with rabbit polyclonal
anti-Fn14 antibody (1:1000, Cell Signaling, Hertfordshire, UK) or
mouse anti-tubulin monoclonal antibody (1:10000, Sigma) followed
by incubation with horseradish peroxidase-conjugated secondary anti-
body (1:2,000, Amersham, Aylesbury, UK). Blots were developed
with the enhanced chemiluminescence method (ECL) following the
manufacturer instructions (Amersham).
2.3. RNA extraction and real time reverse transcription–polymerase chain
reaction
Total RNA was extracted from the tissue and cells by TRI Reagent
method (Sigma) and 1 μg RNA was reverse transcribed with High
Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA).
Pre-developed primer and probe assays (PDAR) for Fn14, TWEAK,
MCP-1, TNF-α and GAPDH (murine) were from Applied (Applied
Biosystems). Quantitative PCR was performed on an ABI Prism 7500
sequence detection PCR system (Applied Biosystems) according to man-
ufacturer's protocol using the Delta Delta Ct method [50]. Expression
levels are given as ratios to GAPDH.
2.4. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were obtained as previously described [51]. Cells
were resuspended in buffer A and homogenized. Nuclei and cytosolic
fractions were separated by centrifugation at 1000 ×g for 10 min. The
nuclei (pellet) were washed twice in buffer A and resuspended in the
same buffer, with a ﬁnal concentration of 0.39 mol/l KCl. Nuclei were
extracted for 1 h at 4 °C and centrifuged at 100,000 ×g for 30 min.
Supernatants were dialyzed in buffer C, cleared by centrifugation and
stored at −80 °C. The protein concentration was determined by the
bicinchonicic acid (BCA) method and transcription factor DNA-binding
activities were assayed [51].
2.5. Elisa
Cells were stimulated with 100 ng/ml TWEAK for 6 h. The concen-
tration of murine MCP-1 in the cell culture supernatants was deter-
mined by ELISA (BD Pharmingen, San Diego, CA).
2.6. Confocal microscopy
Cells plated onto Labtek™ slides were ﬁxed in 4% paraformaldehyde
and permeabilized in 0.2% Triton X-100/PBS for 10 min, washed in PBS
and incubated overnight at 4 °C with rabbit polyclonal anti-RelA (1:75,
Santa Cruz, CA), followed by 1 h incubation with appropriate FITC
secondary antibody (1:200, Sigma). Cell nuclei were counterstained
with propidium iodide. After washing, cells were mounted in 70%
glycerol in PBS, and analyzed with a DM-IRB confocal microscope
(Leica DM, Bannockburn, IL) [51].
The urine sediment fromFSGS patientswas stainedwith rabbit poly-
clonal anti-Fn14 antibody (1:100), and FITC-mouse anti-synaptopodin
(1:10, Progen, Heidelberg, Germany) and DAPI (Sigma). Three FSGS
MN
WT-1
Fn14
FSGS
WT-1
Fn14 
Table 1
Gene expression in glomeruli from FFPE renal biopsy material from the Columbia Renal Pathology Laboratory.
Normal kidney FSGS MCD FSGS vsnormal kidney MCD vs normal kidney
Gene symbol Name Gene id Mean (SD) Mean (SD) Mean (SD) FC p-Value FC p-Value
CCL2 MCP-1 6347 1.59 (1.57) 3.01 (1.68) 1.48 (1.47) 1.89 0.0009 −1.26 0.60
TNFSF12 TWEAK 8742 11.00 (1.40) 10.63 (1.24) 12.13 (1.22) 1.03 0.59 1.1 0.25
TNFRSF12A FN14 51330 2.85 (1.69) 13.93 (2.78) 8.00 (1.66) 4.89 0.001 2.80 0.0008
FC: fold change.
N = 9 normal kidney, 8 FSGS, 7 MCD.
2234 M.D. Sanchez-Niño et al. / Biochimica et Biophysica Acta 1832 (2013) 2232–2243patients were studied (age 48–61 years, 2 males, sCr 1.1–1.5 mg/dl,
albuminuria 0.7–3.9 g/24 h).
2.7. Animal models
For experimental murine protein-overload nephropathy, Fn14 KO
[26] or WT (n = 5/group) mice C57/BL6 weighing 20 g were intraper-
itoneally injected daily with 0.2 g low endotoxin BSA (Sigma, St. Louis,
MO) until the day of sacriﬁce (day 7) [26,59]. WT mice injected with
saline were used as controls. Under general anesthesia kidneys were
perfused with cold saline. One kidney from each mouse was ﬁxed in
buffered formalin, embedded in parafﬁn and used for immunohisto-
chemistry. The other kidney was snap-frozen in liquid nitrogen for
RNA and protein studies [49]. All studies were performed in accordance
with the European Union normative. Based on previous experience
in the lab [59] and the literature, the 7-day time point was chosen as a
time-point when the inﬂammatory response was fully developed.
Urinary albumin excretion was assessed by conventional Coomassie
blue stains and normalized for urinary creatinine. This assay will detect
both endogenous murine albumin and exogenous BSA.
Adenoviral vector expressing soluble TWEAK or control protein GFP
were generated and delivered intravenously as previously described
[25].
2.8. Glomerular isolation
In an independent experiment, two groups of 6 wild type and 6
Fn14.KO mice with BSA nephropathy were studied and compared to
vehicle-treated WTmice (n = 6). A standard sieving isolation protocol
was used [55]. All steps were performed in ice-cold PBS. Kidneys were
perfused with cold PBS. Capsules were removed and the cortex of
each kidney was separated by macroscopic dissection with a sharp
knife. The homogenized tissue was then pushed through four sieves
(150, 72, 53, and 32 μm). The tissue trapped by the 32 μm sieve was
washed with PBS and centrifuged at 4 °C for eight minutes at
1200 r.p.m. The pellet was resuspended in PBS and examined under
phase contrast microscopy. The preparation contained N95% glomeruli
with minimal tubular contamination protein.
2.9. Immunohistochemistry and immunoﬂuorescence
Immunohistochemistry was carried out as previously described in
parafﬁn-embedded tissue sections 5 μm thick [50]. For animal modelTable 2
Gene expression conﬁrmation in glomeruli from frozen renal biopsy material from the
ERCB dataset.
FSGS vs LD MCD vs LD MN vs LD
Gene symbol Name Gene id FC q-Value FC q-Value FC q-Value
CCL2 MCP-1 6347 1.97 0.00 1.37 0.09 1.29 0.02
TNFSF12 TWEAK 8742 1.18 0.00 1.02 0.49 1.14 0.09
TNFRSF12A FN14 51330 1.33 0.01 1.24 0.18 1.64 0.00
FC: fold change, LD: living donor,MN:membranous nephropathy. N = 32 LD, 18 FSGS, 14
MCD, 21 MN.samples, primary antibodies were anti-Fn14 (1:75 Cell signaling),
anti-MCP-1 (1:100, Santa Cruz Biotechnology), anti-RelA (1:60, Santa
Cruz Biotechnology), anti-F4/80 antigen (1:50; Serotec, Oxford, UK),
anti-WT1 (Dako, Denmark) and FITC-mouse anti-synaptopodin (1:10).
Secondary HRP-conjugated antibodies were used. For immunohisto-
chemistry sections were counterstained with Carazzi's hematoxylin.
Negative controls included incubationwith a non-speciﬁc immunoglobu-
lin of the same isotype as the primary antibody. MCP-1 staining was
evaluated by a quantitative scoring system. Image-Pro Plus software
(Media cybernetics, Bethesda, MD) in 10 randomly selected ﬁelds
(20×) per kidney; stained area expressed as percentage of total area.
The number of glomerular F4/80-positive macrophages was quantiﬁed
in 20 randomly chosen ﬁelds (X40) using Image-Pro Plus software.
Samples were examined in a blindedmanner. WT1 positive glomerularFig. 1. Colocalization of Fn14 and the podocyte marker WT-1 in human membranous
nephropathy (MN) and focal segmental glomerulosclerosis (FSGS). In human FSGS and
MN podocytes co-express podocyte markers (WT-1, in blue) and Fn14 (brown)(arrows).
Note also co-expression of both markers in some reactive parietal epithelial cells and
expression of Fn14 in WT-1 negative tubular cells. Magniﬁcation ×200.
2235M.D. Sanchez-Niño et al. / Biochimica et Biophysica Acta 1832 (2013) 2232–2243cells per glomeruli were counted in all glomeruli from a kidney cross-
section per mouse.
2.10. Immunohistochemistry in human samples
Kidney samples were obtained by percutaneous renal biopsy from
patients undergoing diagnostic evaluation for nephrotic syndrome at
the Division of Nephrology (Austral University, Valdivia, Chile). Control
human kidney specimens (N = 5) were taken from normal portions
of renal tissue from patients who underwent surgery because of local-
ized renal tumors. Study samples were MN specimens (n = 13, aged
53 ± 8 years, 6 females, serum creatinine 1.3 ± 0.7 mg/dl, proteinuria
5.4 ± 3.0 g/d), FSGS (n = 11, aged 42 ± 13 years, 5 females, serum
creatinine 1.4 ± 0.6 mg/dl, proteinuria 8.4 ± 5.9 g/d), and MCD
(n = 6, aged 17 ± 16 years, 2 females, serum creatinine 0.4 ±
0.2 mg/dl, proteinuria 5.3 ± 1.5 g/d), Immunohistochemistry was
carried out in parafﬁn-embedded tissue sections 5 μm thick [36].
The primary antibody was rabbit anti-MCP-1 (goat polyclonal IgG,A
B 
C Control kidney 
MCP-1
Membranous ne
MCP-1
Control kidney Membranous nep
Fn14 Fn14
Control kidney 
NF B South Western 
Membranous nep
NF B South W
Fig. 2. Increased podocyte Fn14, NFκB activation and MCP-1 in human membranous nephro
in podocytes in glomeruli of biopsies from human MN and FSGS (arrows). B) Immunohistoch
(A and B correspond to the same MN glomerulus) as well as in FSGS (arrows). C) Podocyte MCAB-279-NA; R&D Systems, Minneapolis, MN), anti-Fn14 (Cell Signaling
Technology, Danvers, MA) or anti-WT-1. Sections were counterstained
with Carazzi's hematoxylin. Negative controls included incubation
with a non-speciﬁc immunoglobulin of the same isotype as the primary
antibody. The local Ethics Committee approved the study protocol and
informed consent was obtained.
2.11. Southwestern histochemistry in human samples
This technique has been described in detail [36]. Synthetic sense
DNA 5′-AGTTGAGGGGACTTTCCCAGGC-3′, which contains a consensus
sequence of NF-κB, and synthetic sense DNA 5′-CGCTTGATGAGTC
AGCCGGAA-3′ (GIBCO BRL, Life Technology, Gaithersburg, MD, USA),
which contains a consensus sequence of AP-1, were used as the probes.
After annealing with their complementary DNA (80 °C during 2 min),
each probe was labeled with digoxigenin (DIG oligonucleotide 3-end
labeling kit; Boehringer Mannheim, Mannheim, Germany). As negative
controls, the following were used: (1) absence of probe; (2) mutantphropathy 
MCP-1
FSGS 
hropathy 
Fn14
FSGS 
hropathy 
estern 
FSGS 
NF B South Western 
pathy and FSGS. A) NFκB activation is demonstrated by South-Western histochemistry
emistry showed increased Fn14 expression in an adjacent section of the same MN biopsy
P-1 expression in human MN and FSGS (arrows). Magniﬁcation ×200.
2236 M.D. Sanchez-Niño et al. / Biochimica et Biophysica Acta 1832 (2013) 2232–2243NF-κB probe (sense 5′-AGTTGAGGCTCCTTTCCCAGGC-3′), labeled with
digoxigenin, at the same concentration as the respective labeled
probe; and (3) competition assays with a 200-fold excess of unlabeled
NF-κB, followed by incubation with labeled probe.
2.12. Human kidney transcriptomics
Two sets of independent transcriptomic data were analyzed. The
ﬁrst transcriptomic array dataset was performed in FFPE renal biopsy
material obtained from the archives of the Columbia Renal PathologyA B
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capture using the PALM Laser Microdissection and Pressure Catapulting
system (PALM MicroBeam IP 230 V Z microscope). Approximately 20
to 25 glomerular cross-sections were captured and pooled from each
case. Only glomeruli without global sclerosis were captured, including
segmentally sclerotic glomeruli, glomeruli with collapsing lesions, and
glomeruli without light microscopic abnormalities. Ampliﬁed target
RNA was hybridized to the Human X3P Array (Affymetrix, Santa Clara,
CA), which is based on the Human Genome U133 plus 2.0 Array
and contains probes for 47,000 transcripts. After scanning according
to standard Affymetrix protocols, raw data were analyzed with BRB-
Array Tools, version 3.7.0 (http://linus.nci.nih.gov/BRB-ArrayTools.
html). Analysis was performed using RobustMultichip Average normal-
ization without a baseline.
The second array dataset was obtained from human renal biopsies
collected in a multicenter study, the European Renal cDNA Bank
(ERCB, Appendix). The biopsies were performed according to the local
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No macrophages were stained in glomeruli from Fn14-KO mice injected with BSA. *p b 0.0001 vs other groups.
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tients and the samples processed according to the ERCB protocol [8].
For oligonucleotide array based gene expression proﬁling a total
of 64 kidney biopsies from individual patients were included, 32A
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2239M.D. Sanchez-Niño et al. / Biochimica et Biophysica Acta 1832 (2013) 2232–22437.33 ± 1.33 g/24 h) and 18 biopsies with histological diagnosis of
FSGS (age 45 ± 4, F:M 8:10, serum creatinine 1.42 ± 0.23 mg/dl,
proteinuria 4.22 ±0.66 g/24 h) and 21 biopsies with histological
diagnosis of MGN (age 54 ± 4, F:M 9:8, serum creatinine
1.05 ± 0.09 mg/dl, proteinuria 4.52 ± 0.69 g/24 h).
Glomeruli were manually microdissected and total RNA was isolated
from the microdissected glomerular tissue as previously described [56]
and hybridized to Affymetrix Human Genome U133A and U133Plus
Genechips (Affymetrix, Inc., Santa Clara, CA) and processed following
the manufacturer's instructions [56]. The raw data was normalized
using Robust Multichip Algorithm (RMA) and annotated by Human
Entrez Gene custom CDF annotation version 10 (http://brainarray.mbni.
med.umich.edu/Brainarray/default.asp). The log transformed dataset
was corrected for batch effect using ComBat [27]. All of these prepro-
cessing was carried out in GenePattern (http://www.broadinstitute.
org/cancer/software/genepattern/) pipeline. SAM (Signiﬁcance analysis
ofMicroarrays; http://www-stat.stanford.edu/~tibs/SAM/)methodwas
used to identify differentially expressed genes [56].2.13. Statistics
For cell culture and animal model data, statistical analysis was
performed using SPSS 11.0 statistical software. Results are expressed
as mean ± s.e.m. Signiﬁcance at the p b 0.05 level was assessed by
Student's t test for two groups of data and ANOVA for three or more
groups with post-hoc Tukey's test.Control TWEAK 
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in cells treated with TWEAK and inhibition by parthenolide. Nuclei stained with propidium iod3. Results
3.1. Increased podocyte Fn14 expression in human proteinuric kidney
disease
Initial studies were performed in glomeruli isolated by laser-capture
microdissection from human renal biopsies of FSGS; the most common
primary glomerular disorder causing ESRD [12]. Transcriptomics of
formalin-ﬁxed, parafﬁn-embedded human biopsies disclosed higher
Fn14 and MCP1 mRNA expression in isolated glomeruli from FSGS
patients than in normal kidneys [22] (Table 1). There was a correlation
between glomerular Fn14 mRNA and MCP-1 mRNA (Suppl. Fig. 1).
Transcriptomic analysis of a second, independent set of human renal
biopsies, conﬁrmed the increased Fn14 and MCP-1 mRNA expression
in glomeruli from FSGSpatientswhen compared to living kidney donors
(Table 2). In addition, this analysis observed increased glomerular Fn14
andMCP-1mRNA in humanMN (Table 2). In FSGS andMN immunohis-
tochemistry disclosed Fn14 expression in WT-1 stained podocytes
(Fig. 1). By contrast, little Fn14 stainingwas observed in control glomer-
uli (Fig. 2.B). In FSGS and MN immunohistochemistry disclosed NFκB
activation in cells in the periphery of the glomerulus with podocyte
morphology (Fig. 2.A). MCP-1 expression was also observed in these
cells (Fig. 2.C). Fn14 positive podocytes were also observed in the
urine of patients with FSGS (Suppl. Fig. 2). Thus, human podocytes
express Fn14, DNA-binding NFκB and MCP-1 in immune and non-
immune proteinuric kidney disease characterized by low-level inﬂam-
mation. Since immune injury may trigger an inﬂammatory response,AK 
6 
TWEAK+Parthenolide 
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response in a non-immune glomerular injury model.
3.2. Increased podocyte Fn14 expression in experimental proteinuric kidney
disease
In order to address the functional in vivo signiﬁcance of the TWEAK/
Fn14 pathway in non-immune, non-proliferative proteinuria, we stud-
ied the protein overload-induced nephropathy model of proteinuria in
mice induced by daily injections of bovine serum albumin (BSA) [59].
Heterologous protein overload induces podocyte injury, resulting in
heterologous as well as autologous proteinuria, in conjunction with
low-level glomerular inﬂammation, leading to tubulointerstitial inﬂam-
mation. In this model, whole kidney Fn14 mRNA and, to a lesser extent,
TWEAK mRNA were signiﬁcantly increased (Fig. 3.A, B). In addition,
increased Fn14 (Fig. 3.C) and TWEAK mRNA (Fig. 3.D) expression was
observed in isolated glomeruli from BSA-overload mice compared
with control mice. Western blot conﬁrmed increased glomerular Fn14
protein in isolated glomeruli from BSA-overload mice compared with
control mice (Fig. 3.E). Finally, increased Fn14 immunostaining in glo-
meruli of BSA-overloaded mice was mainly localized to podocytes and
parietal epithelial cells (Fig. 3.F).
3.3. Fn14 knockout (KO) mice are protected from glomerular inﬂammation
in protein overload-induced proteinuria
Whole kidneyMCP-1mRNA (Fig. 4.A) and isolated glomeruli MCP-1
mRNA (Fig. 4.B) expression was increased in BSA-overloaded WT mice
and this was signiﬁcantly blunted in Fn14 KO mice (Fig. 4.A). Immuno-
histochemistry conﬁrmed signiﬁcantly increased glomerular MCP-1
protein in protein overload WT mice when compared with protein
overload Fn14-KO mice or to control mice (Fig. 4.C, D). Glomerular
MCP-1 expressing cells co-localized with the podocyte-speciﬁc markerA
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experiments. *p b 0.01 vs control; **p b 0.04 vs TWEAK alone.WT-1 in glomeruli of BSA-overload WT mice (Fig. 4.C). A decrease in
podocyte number per glomerulus, determined by WT1-positive cells,
was found in BSA-overload WT mice when compared to control or
Fn14 KO mice (Suppl Fig. 3). TNF-α mRNA expression was increased
in isolated glomeruli from BSA-overload WT mice (Fig. 5) and this was
not observed in Fn14 KO mice (Fig. 5). Finally, cells identiﬁed as
podocytes by synaptopodin co-staining stained for nuclear NFκB RelA
in BSA overloaded WT mice but not in controls and barely in Fn14 KO
mice (Suppl. Fig. 4). This staining procedure suggested decreased
synaptopodin expression in BSA overloaded WT mice as compared to
other groups. Glomerular F4/80 macrophages were increased after
BSA injection in WT mice, but not in Fn14-KO mice injected with BSA
(Fig. 6). In addition, periglomerular F4/80 macrophages were increased
near parietal epithelial cells in BSA-injected WT mice, but not in Fn14-
KO mice (Fig. 6). Albuminuria, assessed by Coomassie blue staining
and adjusted for urine creatinine content did not differ between BSA-
WT and BSA-KOmice (706 ± 339 vs 982 ± 147 A.D.U., ns). No urinary
albumin was observed in non-injected mice.
3.4. Systemic TWEAK overexpression increases periglomerular inﬂammation
Mice were infected with adenovirus expressing TWEAK or the GFP
control protein as previously described, resulting in increased circulat-
ing TWEAK levels [25]. After 21 days, TWEAK overexpressing mice
had periglomerular inﬂammation, which was not observed in GFP
overexpressing mice (Suppl. Fig. 5).
3.5. Cytokines regulate Fn14 expression by cultured podocytes
In light of our ﬁnding that Fn14 is expressed in podocytes in protein-
uric kidney disease, we explored the regulation of Fn14 expression by
cytokines in cultured murine podocytes. TNFα increased Fn14 expres-
sion in podocytes, as assessed by Western blot (Fig. 7.A). An increaseB
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with TNFα and interferon-γ, which frequently accompanies TNFα
during tissue injury (Fig. 7.B, C).
3.6. TWEAKactivates NFκB in podocytes and induces the secretion ofMCP-1
in a NFκB-dependent manner
In cultured podocytes, TWEAK induced a sustained increase in NFκB
DNA-binding activity that peaked at 24 h as assessed by electrophoretic
mobility shift assay (EMSA) (Fig. 8.A). Confocal microscopy showed
an early translocation of RelA from the cytoplasm to the nucleus
(Fig. 8.B). Parthenolide is a sesquiterpeno lactone that inhibits RelA ac-
tivation by preventing the degradation of IκB-α [21,51]. Parthenolide
inhibited RelA translocation induced by TWEAK in podocytes (Fig. 8.B).
We further explored the effect of TWEAKonMCP-1, a canonical RelA
target [44] implicated in experimental glomerular injury [58]. In cul-
tured podocytes TWEAK induces the expression of MCP-1 mRNA in a
dose- and time-dependentmanner (Fig. 9.A, B). Parthenolide prevented
the increase in MCP-1 mRNA and MCP-1 protein secreted to the cell
culture medium, thus conﬁrming that chemokine secretion induced
by TWEAK in podocytes is mediated by NFκB (Fig. 9.C D).
4. Discussion
The main ﬁndings of this study are that glomerular Fn14 expression
is increased in human and experimental non-immune podocyte injury
and proteinuric kidney disease, and that Fn14 contributes to podocyte
injury and glomerular and periglomerular inﬂammation in an experi-
mental model despite the persistence of proteinuria. Thus, we were
able to dissociate the glomerular inﬂammatory response from the pro-
teinuric response by targeting Fn14. Fn14 ampliﬁes the inﬂammatory
response by recruiting chemokines upon engagement by TWEAK.
There is evidence for a role of TWEAK/Fn14 in tubular acute kidney in-
jury and inproliferative, immune-mediated lupus nephritis [37,52]. Activ-
ity of the TWEAK/Fn14 system is regulated mainly through upregulation
of the Fn14 receptor upon tissue injury or cell stress. Glomerular
transcriptomics disclosed upregulation of Fn14 mRNA in human FSGS
and a correlation with the gene expression of the chemokine MCP-1.
This observationwas conﬁrmed in a second, independent transcriptomics
dataset obtained from fresh tissue in RNAlater, as opposed to the parafﬁn
embedding of the ﬁrst dataset. The fact that the cohorts were indepen-
dent, from different continents, obtained in different years and processed
differently (fresh versus parafﬁn-embedded tissue)may justify the differ-
ences in fold-change between cohorts. In the second dataset increased
Fn14 and MCP-1 mRNA were also observed in MN, another progressive
non-proliferative proteinuric kidney disease, but not in MCD. Gene ex-
pression changes were conﬁrmed at the protein level and localized
Fn14 and MCP-1 to podocytes. Furthermore, activation of NFκB was
shown in Fn14-expressing glomerular cells. These data are consistent
with evidence of glomerular NFκB activation, and Fn14 and MCP-1
upregulation obtained in a glomerular transcriptomics study of a rat
model of glomerular aging characterizedbypodocyte stress anddepletion
[64]. Thus, in diverse clinical and experimental situation characterized by
non-proliferative proteinuric podocyte of immune or non-immune injury
share the upregulation of both Fn14 and MCP-1 in the presence of low
level, not overt glomerular inﬂammation [2,24,31]. Low level chronic in-
ﬂammation is now recognized as a key progression factor in diseases
not classically considered inﬂammatory in nature such as atherosclerosis
and diabetic nephropathy. Up to now the role of TWEAK in the glomeru-
lus had only been studied in proliferative, immune-mediated lupus ne-
phritis with overt glomerular inﬂammation. The novel ﬁndings reported
here suggested that TWEAK/Fn14 could be a therapeutic target in glomer-
ular diseases characterized by low-level chronic inﬂammation but lacking
overt inﬂammation and this possibilitywas further exploredby functional
experiments in vivo.Podocytes are the main cells expressing inﬂammatory mediators in
non-proliferative proteinuric kidney diseases [41,42,45], although the
factors responsible for such expression are poorly understood, especial-
ly in non-immune glomerular injury, where an immune trigger cannot
be claimed. Recently, cultured podocytes were shown to express Fn14
[16]. However, the in vivo expression and role of podocyte Fn14 in the
podocyte inﬂammatory response had not been characterized. We now
provide evidence for the importance of Fn14 for the regulation of the
MCP-1 chemokine expression in podocytes in vivo and for glomerular
and periglomerular inﬂammation in non-immune, proteinuric kidney
injury. The protein overload model of proteinuria induced by repeated
BSA administration had been shown to generate low level glomerular
inﬂammation in the murine strain, where Fn14 KOmice were available
[59]. However this strain is resistant to other models of proteinuria.
According to experimental models assessing diverse methods to target
MCP-1 or its receptor in vivo, MCP-1 is a key mediator of kidney injury
induced by non-immunemechanisms such as protein overload [58] and
diabetic nephropathy [13,17,29,57]. Thus, Fn14 deﬁciency most likely
mediated its protective effect on glomerular and periglomerular inﬂam-
mation at least in part by reducingMCP-1 expression. Since albuminuria
was secondary to albumin overload this model did not assess the inﬂu-
ence of Fn14 on albuminuria. In this regard it is of interest that the anti-
inﬂammatory effect of Fn14 targeting was still observed despite the
persistence of albuminuria.
Previous studies on TWEAK/Fn14 and kidney injury had centered in
the tubulointerstitial compartment of the kidney [23,51]. The present
results demonstrate that podocytes are also sensitive to Fn14 activation
in vivo and that Fn14 is a key transducer of proinﬂammatory signals to
podocytes. TWEAK exerted its proinﬂammatory actions in podocytes by
activating the transcription factor NFκB, a key player in the inﬂammato-
ry response of glomerular cells [53]. There is recent interest in the
in vivo podocyte expression of chemokines [19,30,54]. Podocyte and pa-
rietal epithelial cell MCP-1 could contribute to the increased number of
glomerular macrophages observed in protein overload proteinuria in
the present manuscript and in human MN and FSGS, especially in
cases with worse outcome [2,24,31,48]. In addition podocyte MCP-1
could theoretically activate podocyte CCR2 receptors in an autocrine
or paracrinemanner. In podocytesMCP-1 has been reported to promote
motility, actin cytoskeleton rearrangement, apoptosis and decreased
nephrin expression [4,32,40,61]. Podocyte MCP-1 leaking into the glo-
merular ultraﬁltrate could also contribute to tubular cell activation
[63] or appear in urine and be used as a biomarker of kidney inﬂamma-
tion [14,33,62].
In conclusion, upregulation of Fn14 expression appears to be a com-
mon podocyte response to stress in culture and in vivo, in experimental
animals and in humans and in immune and non-immune proteinuric
nephropathies. Fn14 activation drove MCP-1 expression by podocytes
in culture and in vivo and that Fn14 deﬁciency protected against glo-
merular inﬂammation and podocyte injury in non-immune experimen-
tal proteinuria. In this regard, an ongoing clinical trial is exploring the
efﬁcacy and safety if TWEAK neutralization in immune-mediated, pro-
liferative lupus nephritis [47]. Our data provide the preclinical ground-
work for a potential expansion of these clinical studies to non-immune,
non-proliferative proteinuric kidney diseases. The most prevalent of
these are diabetic nephropathy and FSGS [12,15].Author contributions
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